Flow cytometric MRD risk groups in infants with KMT2A-r ALL in the MLL-10 trial
| . | MLL-10 . | ||||
|---|---|---|---|---|---|
| Risk group . | IR no.* . | HR no.* . | Overall no.* . | 3-y and 5-y EFS rates, % (SE) . | P . |
| MRD-LR (negative at TP2 and TP3) | 15 (0) | 24 (6) | 39 (6) | 78.4 (6.8) | |
| MRD-IR (positive at TP2, negative at TP3) | 0 | 9 (3) | 9 (3) | 66.7 (15.7) | |
| MRD-HR (positive or negative at TP2, positive at TP3) | 1 (0) | 8 (8) | 9 (8) | 11.1 (10.5) | <.001 |
| Overall | 16 (0) | 41 (17) | 57 (17) | ||
| . | MLL-10 . | ||||
|---|---|---|---|---|---|
| Risk group . | IR no.* . | HR no.* . | Overall no.* . | 3-y and 5-y EFS rates, % (SE) . | P . |
| MRD-LR (negative at TP2 and TP3) | 15 (0) | 24 (6) | 39 (6) | 78.4 (6.8) | |
| MRD-IR (positive at TP2, negative at TP3) | 0 | 9 (3) | 9 (3) | 66.7 (15.7) | |
| MRD-HR (positive or negative at TP2, positive at TP3) | 1 (0) | 8 (8) | 9 (8) | 11.1 (10.5) | <.001 |
| Overall | 16 (0) | 41 (17) | 57 (17) | ||
TP2, time point 2 (at the end of induction B); TP3, time point 3 (at the end of early consolidation B).
Number in parentheses indicates the number of induction therapy failures or relapses.